Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ACET

Adicet Bio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ACET. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS$-1.70

Adicet Bio, Inc. (NASDAQ: ACET) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:49 UTC.

What Adicet Bio, Inc. does

This clinical stage biotechnology company develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and cancer. The company's approach uses off-the-shelf gamma delta T cells engineered with chimeric antigen receptors that can be derived from unrelated donors, manufactured, stored, and administered without triggering immune rejection. The lead product candidate, prulacabtagene leucel, targets CD20 and is being evaluated in Phase 1 trials across multiple autoimmune conditions including lupus nephritis and systemic lupus erythematosus.

Summarized from Adicet Bio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS$-1.70

Charts

Charts are in the appInteractive charts for ACET are available in Oxford Ledge.
Open ACET in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-07
  • 2026-08-07Chief Medical OfficerStock Option (Right to Buy)Award18,300—
  • 2026-06-23DirectorStock Option (Right to Buy)Award4,200—
  • 2026-06-23DirectorStock Option (Right to Buy)Award4,200—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Adicet Bio, Inc. do?

This clinical stage biotechnology company develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and cancer.

When did ACET last file with the SEC?

Adicet Bio, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:49 UTC. This page is also available as JSON at /api/data?ticker=ACET and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACET and 5,000+ tickers.

Create a free account — keep ACET
For your agent
GET /api/data?ticker=ACET

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt